Overview

• A total of 116,323 drug samples were tested between April 2024 and March 2025, revealing 3,104 not of standard quality and 245 spurious or adulterated products.
• Since December 2022, CDSCO inspections of 905 manufacturing and testing units have led to 694 regulatory actions, including stop-production orders and licence suspensions.
• Authorities launched 961 prosecutions in FY25 against manufacturers, sellers and distributors of spurious or adulterated drugs to bolster legal enforcement.
• Manufacturers whose products fail quality checks are required to immediately recall affected batches and halt further distribution to protect patient safety.
• Under the Strengthening of States’ Drug Regulatory System scheme, ₹756 crore has been released to build 17 new drug testing labs and upgrade 24 existing laboratories.